TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07888088: Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults

Sponsor: Bavarian Nordic · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,014,540

Rescue Site Savings

+$4,621,620

Unlock Full NCT07888088 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07888088 Rescue Dossier →